Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib Plus Protracted Temozolomide in Recurrent Glioblastoma Multiforme
NCT00597493Phase 2Completed
- Sponsor
- Duke University
- Start
- Sep 2007
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in glioblastoma multiforme (GBM), sponsored by Duke University. Primary endpoint: Progression-Free Survival at 6 months. Started Sep 2007; status: completed.
02
Drugs
sorafenib
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00597493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00597493.